Dashboard
Manage Tickers

AKTX Akari Therapeutics Plc

Nasdaq akaritx.com


$ 0.73 $ -0.04 (-4.87 %)    

Tuesday, 04-Nov-2025 10:32:16 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 626.56 $ 3.31 (0.53 %)
DIA $ 472.51 $ 2.20 (0.47 %)
SPY $ 679.70 $ 3.53 (0.53 %)
TLT $ 90.03 $ 0.25 (0.27 %)
GLD $ 364.70 $ 1.10 (0.3 %)
$ 0.725
$ 0.75
$ 0.73 x 147
$ 0.78 x 3,719
$ 0.74 - $ 0.75
$ 0.57 - $ 2.91
47,644
na
472.91M
$ 0.63
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 04-15-2025 12-31-2024 10-K
4 11-19-2024 09-30-2024 10-Q
5 08-19-2024 06-30-2024 10-Q
6 05-15-2024 03-31-2024 10-Q
7 03-29-2024 12-31-2023 10-K
8 05-12-2016 03-31-2016 10-Q
9 03-23-2016 12-31-2015 10-K
10 11-23-2015 09-30-2015 10-Q
11 08-12-2015 06-30-2015 10-Q
12 05-12-2015 03-31-2015 10-Q
13 02-11-2015 12-31-2014 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

akari-therapeutics-appoints-kameel-farag-as-interim-cfo
Akari Therapeutics Appoints Kameel Farag A...
10/23/2025 20:51:08

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
10/15/2025 17:07:00

akari-therapeutics-announces-a-25m-registered-direct-offering-of-3125000-american-depositary-shares-at-080-per-ads
Akari Therapeutics Announces A $2.5M Regis...
10/15/2025 12:37:07

Akari Therapeutics, Plc (NASDAQ:AKTX) (the "Company"), an oncology biotechnology company developing novel payload antib...

akari-therapeutics-files-two-us-provisional-patents-for-ph1-payload-and-combination-adc-therapy-targeting-immune-activation-and-checkpoint-synergy
Akari Therapeutics Files Two U.S. Provisio...
10/09/2025 12:48:06

Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADC...

akari-therapeutics-to-present-splicing-targeted-adc-data-at-sitc-2025-highlighting-immune-activation-and-checkpoint-synergy-in-oral-and-poster-sessions
Akari Therapeutics To Present Splicing-Tar...
10/03/2025 13:34:26

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
09/24/2025 17:06:12

akari-therapeutics-announces-preclinical-data-supporting-ph1-spliceosome-modulating-adc-for-ar-v7driven-prostate-cancer
Akari Therapeutics Announces Preclinical D...
09/24/2025 12:48:07

Data highlights ability of Akari's ADC payload, PH1, to suppress the levels of the AR-V7 receptor that is responsible for d...

akari-therapeutics-files-provisional-patent-application-with-uspto-covering-adc-platform-using-akaris-spliceosome-payload-ph1-for-treating-cancer-by-modulating-alternative-splicing-within-cancer-cells
Akari Therapeutics Files Provisional Paten...
09/17/2025 12:53:55

Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADC...

hc-wainwright--co-reiterates-buy-on-akari-therapeutics-maintains-16-price-target
HC Wainwright & Co. Reiterates Buy on Akar...
09/09/2025 10:29:46

HC Wainwright & Co. analyst Sean Lee reiterates Akari Therapeutics (NASDAQ:AKTX) with a Buy and maintains $1.6 price tar...

akari-therapeutics-enters-ordinary-share-purchase-agreement-with-white-lion-capital-can-sell-up-to-25m-of-shares
Akari Therapeutics Enters Ordinary Share P...
08/29/2025 21:16:07

-SEC Filing

akari-therapeutics-reiterates-research-commitment-on-ph1-spliceosome-modulator-amid-emerging-anti-tumor-potential
Akari Therapeutics Reiterates Research Com...
07/23/2025 12:58:44

PH1 modulates RNA splicing, causing cancer cell death while activating the immune system to attack cancer throughout the bodyCo...

maxim-group-initiates-coverage-on-akari-therapeutics-with-buy-rating-announces-price-target-of-5
Maxim Group Initiates Coverage On Akari Th...
07/18/2025 16:28:21

Maxim Group analyst Jason McCarthy initiates coverage on Akari Therapeutics (NASDAQ:AKTX) with a Buy rating and announces Pr...

akari-therapeutics-secures-indian-patent-for-ph1-spliceosome-inhibitor-payload-and-adc-technology-targeting-cancer
Akari Therapeutics Secures Indian Patent F...
06/18/2025 12:53:33

Differentiated PH1 payload is a spliceosome inhibitor designed to inhibit RNA splicing, leading to cancer cell death and activa...

akari-therapeutics-q1-2025-000-inline-yoy
Akari Therapeutics Q1 2025 $(0.00), Inline...
05/15/2025 12:23:31

Akari Therapeutics (NASDAQ:AKTX) will report on Q1 2025.

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
04/29/2025 21:05:49

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
04/22/2025 21:05:48

akari-therapeutics-fy24-net-loss-from-operations-216m-vs-168m-yoy
Akari Therapeutics FY24 Net Loss From Oper...
04/16/2025 12:07:08

akari-therapeutics-appoints-abizer-gaslightwala-as-president-and-ceo
Akari Therapeutics Appoints Abizer Gasligh...
03/20/2025 12:37:13

Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio of...

akari-therapeutics-announces-76m-private-placement-offering-led-by-existing-shareholders-and-insiders-of-6637626-unregistered-american-depository-shares-at-a-price-of-087-per-ads
Akari Therapeutics Announces $7.6M Private...
03/03/2025 14:10:28

Akari Therapeutics Plc (NASDAQ:AKTX), a biotechnology company developing next-generation precision bi-functional antibody drug ...

akari-therapeutics-announces-samir-r-patel-md-appointed-as-ceo-effective-december-16-2024
Akari Therapeutics Announces Samir R. Pate...
12/18/2024 13:52:12

Samir R. Patel, M.D., appointed as Chief Executive OfficerAbizer Gaslightwala appointed to Board of DirectorsBOSTON and LONDON,...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION